Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UBXSP
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DB-1418
|
|||||
| Synonyms |
DB-1418; AVZO-1418
Click to Show/Hide
|
|||||
| Organization |
Duality Biotherapeutics (DualityBio) (Originator);Avenzo Therapeutics
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
6
|
|||||
| Structure |
|
|||||
|
|
||||||
| Antibody Name |
Anti-EGFR/HER3 bsAb
|
Antibody Info | Antigen Name | |||
| Payload Name |
P1021
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Mc-Gly-Gly-Phe-Gly
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
drozuntecan
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Lung cancer |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
83%
|
|||
| Method Description |
In the EGFR-dominant CAL-27 model, DB-1418 demonstrated a significant tumor growth inhibition (TGI) of 83% at a dose of 1.9 mg/kg Q3W
|
||||
| In Vivo Model | EGFR-dominant CAL-27 model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) |
98%
|
|||
| Method Description |
Notably, in an osimertinib-resistant NSCLC xenograft model with the C797S mutation, DB-1418 induced tumor regression with a TGI of 98% at a dose of 6 mg/kg Q3W.
|
||||
| In Vivo Model | Osimertinib-resistant NSCLC xenograft model with the C797S mutation | ||||
References